Rhumbline Advisers Purchases 33,574 Shares of DexCom, Inc. (NASDAQ:DXCM)

Rhumbline Advisers lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 809,803 shares of the medical device company's stock after purchasing an additional 33,574 shares during the quarter. Rhumbline Advisers owned 0.21% of DexCom worth $55,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Forvis Mazars Wealth Advisors LLC increased its holdings in DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after buying an additional 118 shares during the last quarter. Principal Securities Inc. grew its position in DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after acquiring an additional 135 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Nia Impact Advisors LLC increased its stake in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares during the last quarter. Finally, Level Four Advisory Services LLC raised its holdings in shares of DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now directly owns 105,602 shares of the company's stock, valued at $7,432,268.76. The trade was a 10.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at approximately $10,002,636.06. This represents a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold 83,110 shares of company stock valued at $6,103,505 in the last ninety days. Insiders own 0.32% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Morgan Stanley upped their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Canaccord Genuity Group increased their price objective on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Citigroup reaffirmed a "buy" rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.32.

DexCom Price Performance

Shares of DexCom stock traded down $1.18 during trading on Wednesday, hitting $85.61. 1,857,994 shares of the company's stock traded hands, compared to its average volume of 4,339,558. The company has a market cap of $33.57 billion, a PE ratio of 59.87, a PEG ratio of 2.30 and a beta of 1.43. The firm's fifty day moving average price is $75.28 and its 200 day moving average price is $78.84. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $120.48. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.32 earnings per share. Analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.